Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aurobindo Announces Vaccine Partnership For India

As Dr Reddy's Files For Favipiravir In Canada

Executive Summary

Aurobindo has partnered with US based Covaxx for the first-ever peptide-based COVID-19 vaccine for the Indian market. While Dr Reddy’s has filed for favipiravir in Canada, Cipla has launched its second antigen detection test kit in India. And the Serum Institute of India will be providing Bangladesh with Oxford-AstraZeneca vaccine doses via Beximco

You may also be interested in...

Dr Reddy’s Accelerates Vaccine Efforts

Dr Reddy’s is collaborating with the Indian government’s biotechnology department to conduct Sputnik V vaccine clinical trials In India, after it received approval from the DCGI. Pfizer’s CEO has offered an update on the development and distribution of the COVID-19 vaccine that it is developing in partnership with BioNTech. Cipla has launched COVID-19 antibody detection kits for India. And the WHO has called for management of the coronavirus “infodemic.”

After Glenmark, Dr Reddy’s Launches Favipiravir For Indian Market

While Dr Reddy’s partners with Fujifilm Toyama for favipiravir for the Indian market, Pfizer and Gilead join together to increase the manufacturing and supply of investigational antiviral treatment remdesivir. Mylan donates a million dollars to Sesame Workshop to provide socio-emotional support to children and families to cope with the uncertainties caused by COVID-19, while Glenmark introduces a higher strength of Fabiflu for the Indian market.

Billionaire Mark Cuban Surprises With US Generics Venture

 To increase transparency and affordability, American billionaire and businessman Mark Cuban has launched a US generics venture under the name ‘the Mark Cuban Cost Plus Drugs Company.’ Cuban’s new company is hoping to introduce over 100 drugs by the end of 2021 and build a pharmaceutical factory of its own by 2022. 


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts